These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 1733754)
1. Valproate therapy induces von Willebrand disease type I. Kreuz W; Linde R; Funk M; Meyer-Schrod R; Föll E; Nowak-Göttl U; Jacobi G; Vigh Z; Scharrer I Epilepsia; 1992; 33(1):178-84. PubMed ID: 1733754 [TBL] [Abstract][Full Text] [Related]
2. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. Serdaroglu G; Tütüncüoglu S; Kavakli K; Tekgül H J Child Neurol; 2002 Jan; 17(1):41-3. PubMed ID: 11913569 [TBL] [Abstract][Full Text] [Related]
3. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Koenig S; Gerstner T; Keller A; Teich M; Longin E; Dempfle CE Blood Coagul Fibrinolysis; 2008 Jul; 19(5):375-82. PubMed ID: 18600085 [TBL] [Abstract][Full Text] [Related]
4. Valproate-associated coagulopathies are frequent and variable in children. Gerstner T; Teich M; Bell N; Longin E; Dempfle CE; Brand J; König S Epilepsia; 2006 Jul; 47(7):1136-43. PubMed ID: 16886976 [TBL] [Abstract][Full Text] [Related]
5. Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare. Eberl W; Budde U; Bentele K; Christen HJ; Knapp R; Mey A; Schneppenheim R Hamostaseologie; 2009 May; 29(2):137-42. PubMed ID: 19404518 [TBL] [Abstract][Full Text] [Related]
6. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
7. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level. Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190 [TBL] [Abstract][Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
9. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
10. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Michiels JJ; van Vliet HH Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362 [TBL] [Abstract][Full Text] [Related]
11. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and spectrum of von Willebrand disease from western India. Trasi S; Shetty S; Ghosh K; Mohanty D Indian J Med Res; 2005 May; 121(5):653-8. PubMed ID: 15937368 [TBL] [Abstract][Full Text] [Related]
13. Platelet-type von Willebrand disease platelet aggregating factor: a novel functional assay of von Willebrand factor. Takahashi H; Tatewaki W; Hanano M; Shibata A Thromb Res; 1987 Nov; 48(4):475-85. PubMed ID: 3127926 [TBL] [Abstract][Full Text] [Related]
15. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239 [TBL] [Abstract][Full Text] [Related]
16. Von Willebrand's disease: case report and review of literature. Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675 [TBL] [Abstract][Full Text] [Related]
17. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [TBL] [Abstract][Full Text] [Related]
18. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. Miller JL; Kupinski JM; Castella A; Ruggeri ZM J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113 [TBL] [Abstract][Full Text] [Related]
19. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962 [TBL] [Abstract][Full Text] [Related]
20. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease. Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]